About | Free Trial

Last Update

2014-11-23T00:00:00.000Z

This profile was last updated on // .

Is this you? Claim your profile.

Wrong Ronald Jones?

Dr. Ronald Jones N. MD

President, Chief Executive Officer

JMI Laboratories

HQ Phone: (319) 665-3370

Email: j***@***.com

JMI Laboratories

345 Beaver Kreek Centre Suite A

North Liberty, Iowa 52317

United States

Company Description

JMI Laboratories serve as specialists in anti-infectives (antibacterials, antifungals and antiseptics) research. Our mission is to assist our clients with their antimicrobial development needs by providing and delivering those required services to the hig ... more

Find other employees at this company (30)

Background Information

Employment History

Ron Jones Manager - Purchasing and Logistics
Laser Spine Institute

Affiliations

Fellow
Infectious Diseases Society of America

Member
U.S. Pharmacopeia

Scientific Advisor
Cerexa , Inc.

Numerous Committees
Clinical and Laboratory Standards Institute

Education

MD

medical degree

University of Oregon

Web References (35 Total References)


Advisors | Seachaid Pharmaceuticals

www.seachaid.com [cached]

Ron Jones, MD - Dr. Jones is an Adjunct Professor of Medicine at Tufts University School of Medicine in Boston, Massachusetts and is President/CEO of JMI Laboratories. He is a fellow in the American Society of Clinical Pathologists, the College of American Pathologists, the American Academy of Microbiology, the Infectious Disease Society of America and numerous other organizations. He has served on or chaired numerous committees or subcommittees of the Clinical and Laboratory Standards Institute (formerly the National Committee for Clinical Laboratory Standards) over the last 30 years (recipient of the Eilers Award in 2001, the highest award given by the CLSI), and also as a member of the advisory council for antimicrobial agents of the U.S. Pharmacopeia. Dr. Jones has authored over 1,600 peer-reviewed publications on a variety of topics relating to the comprehensive evaluation of new antimicrobial agents, antimicrobial susceptibility test development, and resistance mechanisms and their phenotypic expression or molecular epidemiology. He has also authored a number of book chapters, hundreds of abstracts, pamphlets, and monographs, sits on the editorial board of several international peer-reviewed journals, and is currently the Editor-in-Chief of Diagnostic Microbiology and Infectious Disease, a well known international publication. He has been the principal global investigator for the SENTRY Antimicrobial Surveillance Program and the MYSTIC Programme, as well as a regional monitor for other resistance surveillance networks (ZAPS, ZAAPS, SMART, LEADER, SPAR, SCOPE, AWARE, etc). Dr. Jones obtained his medical degree from the University of Oregon, where he also served an internship and residency in Anatomic and Clinical Pathology. He is board certified in anatomic and clinical pathology by the American Board of Pathology.


Ronald Jones, ...

www.zavantetherapeutics.com [cached]

Ronald Jones, MD

Dr. Ronald Jones is an Adjunct Professor of Medicine at Tufts University School of Medicine in Boston, Massachusetts and is President/CEO of JMI Laboratories. He is a fellow in the American Society of Clinical Pathologists, the College of American Pathologists, the American Academy of Microbiology, the Infectious Disease Society of America and numerous other organizations.
He has served on or chaired numerous committees or subcommittees of the Clinical and Laboratory Standards Institute (formerly the National Committee for Clinical Laboratory Standards) over the last 25 years (recipient of the Eilers Award in 2001, the highest award given by the CLSI), and is also a member of the advisory council for antimicrobial agents of the U.S. Pharmacopeia. Dr. Jones has authored over 1,300 peer-reviewed publications on a variety of topics relating to the comprehensive evaluation of new antimicrobial agents, antimicrobial susceptibility test development, and resistance mechanisms and their phenotypic expression or molecular epidemiology. He has also authored a number of book chapters, hundreds of abstracts, pamphlets, and monographs, sits on the editorial board of several international peer-reviewed journals, and is currently the Editor-in-Chief of Diagnostic Microbiology and Infectious Disease, a well known international publication.
He has been the principal global investigator for the SENTRY Antimicrobial Surveillance Program and the MYSTIC Programme, as well as a regional monitor for other resistance surveillance networks (ZAPS, ZAAPS, SMART, LEADER, SPAR, SCOPE etc). Dr. Jones obtained his medical degree from the University of Oregon, where he also served an internship and residency in Anatomic and Clinical Pathology. He is board certified in anatomic and clinical pathology by the American Board of Pathology.


Ronald Jones, ...

www.zavantetherapeutics.com [cached]

Ronald Jones, MD

Dr. Ronald Jones is an Adjunct Professor of Medicine at Tufts University School of Medicine in Boston, Massachusetts and is President/CEO of JMI Laboratories. He is a fellow in the American Society of Clinical Pathologists, the College of American Pathologists, the American Academy of Microbiology, the Infectious Disease Society of America and numerous other organizations.
He has served on or chaired numerous committees or subcommittees of the Clinical and Laboratory Standards Institute (formerly the National Committee for Clinical Laboratory Standards) over the last 25 years (recipient of the Eilers Award in 2001, the highest award given by the CLSI), and is also a member of the advisory council for antimicrobial agents of the U.S. Pharmacopeia. Dr. Jones has authored over 1,300 peer-reviewed publications on a variety of topics relating to the comprehensive evaluation of new antimicrobial agents, antimicrobial susceptibility test development, and resistance mechanisms and their phenotypic expression or molecular epidemiology. He has also authored a number of book chapters, hundreds of abstracts, pamphlets, and monographs, sits on the editorial board of several international peer-reviewed journals, and is currently the Editor-in-Chief of Diagnostic Microbiology and Infectious Disease, a well known international publication.
He has been the principal global investigator for the SENTRY Antimicrobial Surveillance Program and the MYSTIC Programme, as well as a regional monitor for other resistance surveillance networks (ZAPS, ZAAPS, SMART, LEADER, SPAR, SCOPE etc). Dr. Jones obtained his medical degree from the University of Oregon, where he also served an internship and residency in Anatomic and Clinical Pathology. He is board certified in anatomic and clinical pathology by the American Board of Pathology."


The building is owned by Dr. ...

www.northlibertyleader.com [cached]

The building is owned by Dr. Ronald Jones, founder and president of JMI Laboratories, the business that occupies the lower level of building 345 and also the lower part of the adjacent building. JMI is a microbiology research laboratory that produces information from bacteria sent from around the world, Jones said. "Quite basically, we do testing on how well antibiotics kill bacteria," Jones said. "This work is contracted from large and small pharmaceutical companies all over the world, and the information is used to approve for clinical use antibiotics for use in the United States and Europe" Dr. Jones said there were three critical things saved from harm in last week's fire. "The first is the people," Jones said. "They were not compromised or hurt, which is the most important thing. Secondly, there is information we have accumulated over 12 years on our computers. All of that was saved because of the secured servers, and none of that absolutely priceless information was lost" The third crucial save, he said, was saving the bugs. "We have a collection of bacteria in the hundreds of thousands of strains," Dr. Jones said. "They are secured in minus 80 degree centigrade freezers (-112 Fahrenheit), huge freezers that weigh about one ton apiece" Firefighters helped JMI employees wheel the freezers out of the burning building, through the parking lot and into JMI's adjacent building. "We got them powered up with gas generators very quickly, so we didn't lose any of those, either" In fact, Dr. Jones added, all of JMI's equipment and services were transferred to its other building and was operational in less than 16 hours. Dr. Jones also credited the built-in fire separation walls for helping to abate the fire and keep damage to a minimum. "The contractor and developer of these buildings, Keith Hodapp, was here on the premises while it was still burning," said Dr. Jones.

...
She walked out in the parking lot behind the buildings, saw the back part was on fire, and immediately called the fire department and then ran to the building to warn our employees," Dr. Jones said.


The findings were presented in two ...

www.kipling.thefreelibrary.com [cached]

The findings were presented in two posters titled, "Dalbavancin Surveillance Results for European Gram-positive Species in a Contemporary (2006-2009) Sample of 23,825 Strains" and "Dalbavancin Activity and Spectrum Evaluated Against a Contemporary (2007-2009) Worldwide Collection of Staphylococci (62,590 strains)," based on results from Dr. Ron Jones and his coauthors at the Jones Microbiology Institute ( JMI JMI Java Metadata Interface (Sun Microsystems)

...
Dr. Jones, President and Chief Executive Officer of JMI Laboratories, commented, "From our resistance surveillance program results presented at the ECCMID ECCMID European Society of Clinical Microbiology and Infectious Diseases meeting (Milan) for 62,590 staphylococci sampled worldwide, we can predict that this drug will inhibit all MRSA at less than or equal to 0.5 milligrams per liter. This level of activity was consistent over time (2006 to 2009), across geographic regions (USA and Europe), and was four- to 16-fold more potent than vancomycinvancomycin(vn'km`sn), antibiotic resembling penicillin in the way it acts. It is derived from the bacterium Streptomyces orientalis, which was isolated from soil of India and Indonesia. , daptomycin and linezolid."
Dr. Jones continued, "The convenient, once-daily dalbavancin dosing regimen for projected acute bacterial skin and skin structure infection trials in future clinical practice will be a welcome addition to MRSA therapies in various clinical settings, including hospitals, emergency rooms and out-patient intravenous treatment programs."

Similar Profiles

Other People with this Name

Other people with the name Jones

Tyus Jones
Minnesota Timberwolves

Bebe Jones
CUSP Magazine LLC

Rachael Jones
Stonington Volunteer Ambulance Corps Inc

Mike Jones
Levotape Twitter

Kimberly Jones
Butler/Till

Browse ZoomInfo's Business Contact Directory by City

Browse ZoomInfo's
Business People Directory

Browse ZoomInfo's
Advanced Company Directory